MBA, Marketing
Indiana University, Indianapolis, IN
MS, Chemistry, Organic
Purdue University, Indianapolis, IN
BA, Chemistry and German
Smith College, Northhampton, MA
Kati Copley-Merriman has more than 35 years of industry experience, including leadership roles in Global Outcomes Research at Eli Lilly, Parke-Davis, and Pfizer. Ms. Copley-Merriman has experience in all aspects of outcomes research and many therapeutic areas, including oncology, pain and inflammation, dermatology, respiratory, urology, and central nervous system. In her role at RTI-HS role, she leads a team of outcomes research scientists, medical writers, and reimbursement experts responsible for developing outcomes research strategic plans, literature reviews, disease-state summaries, global value dossiers, and reimbursement dossiers. Ms. Copley-Merriman is an active member of International Society for Pharmacoeconomics and Outcomes Research and served on its Board of Directors from 2010 to 2012. She was also appointed as a member of the editorial advisory board of the journal Value in Health for November 2014 to November 2022.